ArticleAnnals of clinical microbiology and antimicrobials2026
Emergence of hypervirulent ESBL-producing Klebsiella pneumoniae with high virulence and antibiotic resistance in Southwest of Iran.
Article in Annals of clinical microbiology and antimicrobials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phenotypic and Genetic Profile, Biofilm-Forming Ability and Antibiotic Sensibility of ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigates the prevalence of hypervirulent Klebsiella pneumoniae (hvKp) in clinical isolates, emphasizing hypermucoviscosity, virulence-related genes, capsular serotype, and extended-spectrum β-lactamase (ESBL) genes.
methodsDuring a 12-month surveillance study, a total of 144 K. pneumoniae isolates were obtained from various clinical specimens of patients referred to teaching hospitals in Yasuj, Iran. Antimicrobial susceptibility testing was performed for various classes of antibiotics using the disk diffusion method. Detection of virulence genes (rmpA, rmpA2, iucA, peg-344), capsular serotype (K1, K2), and ESBLs (blaSHV, blaTEM, blaCTX-M) was conducted using polymerase chain reaction (PCR).
resultsA total of 31 isolates (21.5%) were identified as hvKp, while 113 (78.5%) were classified as cKp. Among hvKp, iucA (100%) and rmpA2 (77.4%) were the most prevalent virulence genes, while among all K. pneumoniae isolates, rmpA, rmpA2, and iucA were detected in 11.1%, 16.7% and 21.5%, respectively. Capsular serotype K2 was found in 21.5% of isolates and 9.7% of hvKp, while serotype K1 was not detected in any isolate. ESBL production was observed in 22.2% of isolates and 22.6% of hvKp. Genotypically, blaSHV, blaCTX-M, and blaTEM were identified in 88.9%, 69.4%, and 58.3% of isolates and in 90.3%, 100%, and 74.2% of hvKp, respectively. The highest resistance to third-generation cephalosporins, including cefotaxime, ceftazidime, and ceftriaxone, was observed among all 144 K. pneumoniae isolates as well as hypervirulent strains, whereas gentamicin showed the highest susceptibility. Multidrug-resistant (MDR), extensively drug-resistant (XDR), and carbapenem-resistant K. pneumoniae (CRKP) were identified in 72.9%, 59.7%, and 79.2% of isolates, respectively. In comparison, all these resistance phenotypes were observed in 90.3% of hvKp strains.
conclusionsThese findings demonstrate strong coexistence of virulence and resistance in K. pneumoniae, particularly among hvKp. The high prevalence of virulence factors such as iucA (100%) and rmpA2 (77.4%), with MDR, XDR, and CRKP phenotypes detected in 90.3% of hvKp isolates, indicates a critical situation and emphasizes the need for accurate molecular diagnosis, continuous monitoring, and rational antibiotic use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.